PEOPLE ON THE MOVE
Outpost Medicine: Scott Byrd
Scott Byrd has been appointed president and CEO of Outpost Medicine, a firm which develops treatments for urologic and gastrointestinal disorders.
Chairman Tachi Yamada said Byrd will be instrumental in progressing the firm’s pipeline.
“Scott has a proven record of success across commercialisation, development, manufacturing, and capital markets, which we expect will greatly benefit Outpost as we advance our pipeline of novel therapeutics,” he said in a statement.
Byrd told us he is look forward to contributing to the development of the firm’s lead candidate OP-687, indicated to treat patients suffering from overactive bladder and irritable bowl syndrome.
“I am acutely focused on aggressively advancing OP-687 through its development and continuing to build out our world-class team leadership team,” he said.
Byrd will leave his current position as president and chief operation officer of Acacia Pharma to take on the role.
He has previously held positions at Cadence Pharmaceuticals and Eli Lilly, and holds a bachelor of science in mechanical engineering from Bradley University, and an MBA from Harvard Business School.
